|Bid||0.00 x 800|
|Ask||0.00 x 3000|
|Day's Range||3.21 - 3.54|
|52 Week Range||2.66 - 6.40|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Opko Health (OPK) is focused on advancing multiple research and development (or R&D) programs including label expansion of Rayaldee and the development of novel therapies in 2018.
Wall Street analysts expect Opko Health to report selling, general, and administrative (or SG&A) expenses of $365.60 million in fiscal 2018, which would be a YoY decline of 29.83%. The company is expected to witness SG&A expenses of $437.64 million in fiscal 2019, which would be a YoY rise of 19.70%. Wall Street analysts also expect Opko Health to report SG&A expenses of $491.90 million in fiscal 2020, which would be a YoY rise of 12.40%.
In its third-quarter earnings conference call, Opko Health (OPK) forecasted its total product revenues to fall in the range of $28 million to $32 million in the fourth quarter. The company also reported Rayaldee sales of $5.8 million in the third quarter, which is a 21% rise on a sequential basis. Rayaldee witnessed a 222% YoY rise and an 18% sequential rise in prescription volumes in the third quarter.
Opko Health (OPK) is focused on advancing the penetration of its 4Kscore blood test. Opko Health has witnessed a 19% YoY rise in urologists performing 4Kscore blood tests in the 12 months ending September 2018. On May 18, Opko Health issued a press release announcing its plans to ensure Medicare coverage for the 4Kscore blood test despite the non-coverage policy proposed by Novitas Solutions.
In its third-quarter earnings conference call, Opko Health (OPK) forecasted that its revenues from services will fall in the range of $185 million to $205 million in the fourth quarter. Wall Street analysts expect Opko Health to report revenues of $1.04 billion in fiscal 2018, which would be a YoY decline of 2.59%. Wall Street analysts expect Opko Health to report revenues of $1.27 billion in fiscal 2020, which would be a YoY rise of 13.54%.
On November 9, Opko Health (OPK) closed at $3.09, which was 11.46% lower than its previous closing price. The stock was trading 15.57% lower than its closing price of $3.66 on November 1. To know more about the major events that had a significant impact on Opko Health’s stock price, read Why Opko Health Rose 15% Yesterday.
OPKO Health (OPK) delivered earnings and revenue surprises of 37.50% and -4.85%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Miami-based company said it had a loss of 5 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of ...
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
On September 7, the Securities and Exchange Commission (or SEC) announced that it would be filing charges against Opko Health’s (OPK) founder and CEO, Phillip Frost, and ten associated entities including Opko Health and Frost Gamma Investments Trust for indulging in fraudulent schemes to manipulate stock prices of certain companies. The agency claimed that a group of microcap fraudsters used classic pump-and-dump schemes and illegal promotional means to artificially inflate the stock prices of MabVax Therapeutics Holdings and BioZone Pharmaceuticals, which subsequently led to $27 million worth of illegal stock sales. Following these allegations, Opko Health stock fell 18.06% to $4.58 on September 7. Afterward, Nasdaq halted the trading of the stock and requested additional information from the company related to the SEC’s lawsuit.
Frost is a former chairman of Teva, and two of the companies involved in the alleges schemes were in the biopharmaceutical sector.
It wasn’t a screaming bullish finish to the week, but it didn’t matter. The S&P 500’s 0.03% gain on Friday translated into a 1.1% advance for the five-day span. The close of 2,904.98 was the second-best close ever.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. OPKO Health’s insiders have invested 444.52kRead More...
Financier Barry Honig, Opko Health Inc. (NASDAQ: OPK ) and Riot Blockchain, Inc. (NASDAQ: RIOT ) CEO John O'Rourke were among those named as defendants in a securities fraud lawsuit filed Friday by the ...